{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"185","value":"658"},{"groupId":"OG001","spread":"210","value":"793"}]}],"title":"Trastuzumab Deruxtecan"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"208","value":"697"},{"groupId":"OG001","spread":"261","value":"829"}]}],"title":"Total Anti-HER2 Antibody"},{"categories":[{"measurements":[{"groupId":"OG000","spread":".022","value":".050"},{"groupId":"OG001","spread":".017","value":".059"}]}],"title":"DXd (Metabolite Active Metabolite MAAA-1181a)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan 5.4 mg/kg"},{"description":"Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG001","title":"Trastuzumab Deruxtecan 6.4 mg/kg"}],"paramType":"MEAN","populationDescription":"The PK Analysis Set included all randomized subjects who received at least one dose of study drug and had any measurable post-dose serum concentrations of T-DXd, total anti-HER2 antibody, and DXd.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)","title":"Pharmacokinetic Parameter Area Under the Serum Concentration-Time Curve (AUC) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a","type":"SECONDARY","unitOfMeasure":"µg × d/mL"}